Bailard Inc. Sells 9,850 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bailard Inc. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.0% in the 4th quarter, Holdings Channel reports. The firm owned 55,668 shares of the medical device company’s stock after selling 9,850 shares during the quarter. Bailard Inc.’s holdings in DexCom were worth $6,908,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of DexCom by 3.3% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,703 shares of the medical device company’s stock valued at $1,204,000 after acquiring an additional 307 shares in the last quarter. Atria Wealth Solutions Inc. increased its stake in shares of DexCom by 73.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 6,290 shares of the medical device company’s stock valued at $781,000 after acquiring an additional 2,674 shares in the last quarter. Harvest Fund Management Co. Ltd increased its stake in shares of DexCom by 11.2% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 3,395 shares of the medical device company’s stock valued at $415,000 after acquiring an additional 343 shares in the last quarter. GAMMA Investing LLC bought a new stake in shares of DexCom in the 4th quarter valued at $325,000. Finally, Linden Thomas Advisory Services LLC increased its stake in shares of DexCom by 2.5% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 13,376 shares of the medical device company’s stock valued at $1,660,000 after acquiring an additional 330 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Finally, Raymond James lifted their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $141.40.

DexCom Stock Performance

DexCom stock traded up $0.38 during midday trading on Thursday, reaching $138.25. The stock had a trading volume of 2,407,701 shares, compared to its average volume of 2,950,494. The firm’s 50-day moving average price is $130.58 and its 200 day moving average price is $117.88. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The firm has a market capitalization of $54.75 billion, a PE ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.34 earnings per share. As a group, research analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 49,633 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock valued at $25,530,859. 0.41% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.